These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 15093804)

  • 1. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitors in heart transplantation.
    Keogh A
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset diabetes after transplantation.
    Marchetti P
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S194-201. PubMed ID: 15093805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
    Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
    Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.
    Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD
    J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
    Jardine AG
    Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular disease after renal transplantation].
    Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    G Ital Nefrol; 2004; 21 Suppl 26():S53-66. PubMed ID: 15732047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E; Kushwaha SS
    Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New-onset cardiovascular risk factors in lung transplant recipients.
    Silverborn M; Jeppsson A; Mårtensson G; Nilsson F
    J Heart Lung Transplant; 2005 Oct; 24(10):1536-43. PubMed ID: 16210127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H; Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant coronary disease: nonimmunologic risk factors.
    Johnson MR
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S124-32. PubMed ID: 1622991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitors in heart transplantation.
    Crespo-Leiro MG
    Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
    Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
    J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
    Ward HJ
    J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
    Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
    Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risks of cardiovascular disease in liver allograft recipients.
    Mells G; Neuberger J
    Transplantation; 2007 May; 83(9):1141-50. PubMed ID: 17496526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H; Hetzer R
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.